Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: An earlier analysis of this phase 3 trial showed that the addition of a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor to endocrine therapy provided a greater benefit with regard to progression-free survival than endocrine therapy alone in premenopausal or perimenopausal patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Here we report the results of a protocol-specified interim analysis of the key secondary end point of overall survival. METHODS: We randomly assigned patients to receive either ribociclib or placebo in addition to endocrine therapy (goserelin and either a nonsteroidal aromatase inhibitor or tamoxifen). Overall survival was evaluated with the use of a stratified log-rank test and summarized with the use of Kaplan-Meier methods. RESULTS: A total of 672 patients were included in the intention-to-treat population. There were 83 deaths among 335 patients (24.8%) in the ribociclib group and 109 deaths among 337 patients (32.3%) in the placebo group. The addition of ribociclib to endocrine therapy resulted in significantly longer overall survival than endocrine therapy alone. The estimated overall survival at 42 months was 70.2% (95% confidence interval [CI], 63.5 to 76.0) in the ribociclib group and 46.0% (95% CI, 32.0 to 58.9) in the placebo group (hazard ratio for death, 0.71; 95% CI, 0.54 to 0.95; P = 0.00973 by log-rank test). The survival benefit seen in the subgroup of 495 patients who received an aromatase inhibitor was consistent with that in the overall intention-to-treat population (hazard ratio for death, 0.70; 95% CI, 0.50 to 0.98). The percentage of patients who received subsequent antineoplastic therapy was balanced between the groups (68.9% in the ribociclib group and 73.2% in the placebo group). The time from randomization to disease progression during receipt of second-line therapy or to death was also longer in the ribociclib group than in the placebo group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.55 to 0.87). CONCLUSIONS: This trial showed significantly longer overall survival with a CDK4/6 inhibitor plus endocrine therapy than with endocrine therapy alone among patients with advanced hormone-receptor-positive, HER2-negative breast cancer. No new concerns regarding toxic effects emerged with longer follow-up. (Funded by Novartis; MONALEESA-7 ClinicalTrials.gov number, NCT02278120.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in view of the OS benefit seen in several trials,36, 37, 38, 39, 40, 41, 42 both in the first- and second-line settings”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“The last 2 years have seen the establishment of cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET) as the standard of care for ER-positive/HER2-negative ABC”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“substantial PFS benefit and good toxicity profile.36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“the combination of tamoxifen and ribociclib led to increased cardiotoxicity (arrhythmia)”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“These agents can be combined with an aromatase inhibitor (AI) or fulvestrant, and are effective in de novo or recurrent ABC, in first or second line, in cases of primary or secondary resistance, in postmenopausal and premenopausal women (the latter with ovarian function suppression/ablation), and in men (preferably with a luteinising hormone-releasing hormone agonist).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Self-citationFinn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Self-citationSledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680
Self-citationOverall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810527 · Cited by 1,276
Self-citation4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,171
Self-citationSlamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9909 · Cited by 1,121
Self-citation
Cited by
Items 801–900 of 1,000
Zhukova, L., & Mukhina, M. A. (2020) · Tumors of female reproductive system · doi:10.17650/1994-4098-2020-16-1-32-36
Mammakarzinom: Therapieergänzung zeigt große Wirkung
Banys‐Paluchowski, M. (2020) · Kompass Onkologie · doi:10.1159/000508013
Бесова, Н. С. (2020) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2020-9-27-42 · Cited by 1
Clinical aspects of the use of ribociclib
Маркович, А. А., Kalugin, M. V., Гордеева, О. О., & Yakoobova, M. Z. (2020) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2020-9-44-56
Kolyadina, I. V., Петровна, Г. И., Викторовна, К. С., Иссаевна, Т. А., Kolokolov, J. J., Викторович, В. М., & Poddubnaya, I. V. (2020) · Journal of Modern Oncology · doi:10.26442/18151434.2020.2.200212 · Cited by 1
In the literature: August 2020
Gambardella, V., Cejalvo, J. M., Tarazona, N., & Cervantes, A. M. R. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000909
Untch, M., Würstlein, R., Lüftner, D., Haidinger, R., Fasching, P. A., Augustin, D., Briest, S., Ettl, J., Forster, F. M. C., Kurbacher, C. M., et al. (2020) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/a-1205-4313
Self-citationWhy CDK 4/6 Inhibitors are Practice Changing in Advanced Breast Cancer
McAndrew, N. P., & McCann, K. E. (2020) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2020.16.1.23 · Cited by 1
“6 months.(46) This survival benefit held true across all subgroups.”
BackgroundPreuß, C., Hein, A., Beckmann, M. W., & Jud, S. M. (2020) · Der Klinikarzt · doi:10.1055/a-1298-3661
“Das Gesamtüberleben im Ribociclib-Arm betrug nach 42 Monaten 70,2 % in der Ribociclib-Gruppe (95 % CI, 63,5–76,0) und 46,0 % (95 % CI, 32,0–58,9) in der Placebo-Gruppe [HR für Tod 0,71(95 % CI, 0,54– 0,95) p = 0,00973 im Log-rank Test) [17].”
Systemic Therapy for the Treatment of Breast Cancer
Leon, A. C. S., & Richardson, A. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-72166-0.00008-6
Efficiency and tolerability of abemaciclib in elderly patients
Kovalenko, E. I., Khoroshilov, M. V., & Артамонова, Е. В. (2020) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2020-20-32-38
Update Mammakarzinom 2020 Teil 4 – fortgeschrittenes Mammakarzinom
Tesch, H., Müller, V., Wöckel, A., Ettl, J., Belleville, E., Schütz, F., Hartkopf, A. D., Thill, M., Huober, J., Fasching, P. A., et al. (2021) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/a-1331-8621
Ipao (2021) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.4737351
Claussen, C., & Rody, A. (2021) · Der Gynäkologe · doi:10.1007/s00129-021-04792-7
Kolyadina, I. V., Abidova, N. R., Александрович, А. А., Antonova, G. V., Игоревна, А. О., Анатольевна, Б. Э., Болотина, Л. В., Valiakhmetova, C. К., Vasilevskaya, A. V., Vladimirova, L. Y., et al. (2021) · Journal of Modern Oncology · doi:10.26442/18151434.2021.1.200769
Ryspayeva, D. (2021) · Practical oncology · doi:10.22141/2663-3272.4.1.2021.229867
Hormonresistenz in der Mammakarzinomtherapie
Steinberg, M., Radke, I., & Kiesel, L. (2021) · Gynäkologische Endokrinologie · doi:10.1007/s10304-021-00392-9
“ZuweiterenNebenwirkungenkönnen Müdigkeit, Übelkeit, Anämie, Haarausfall und Durchfall gehören [11].”
BackgroundCharacteristics and therapy of advanced cancer diseases
Taghizadeh, H. (2021)
The Systemic Exclusion of Native Americans from Cancer Clinical Trials
Cayatineto, H. W., Clyde, C. S., Yazzie, G. A., Selassie, G., & de Soto, J. A. (2021) · Research Review · doi:10.52845/jmrhs/2021-4-8-4
Quintero-Ortíz, M. A., Briceño-Morales, X., Sánchez-Castillo, O., Velásquez, J. C., Bonilla, C., Guzmán-Abisaab, L., Cervera, S., Bruges, R. E., Ángel-Aristizábal, J., Duarte, C., et al. (2021) · Revista Colombiana de Cancerología · doi:10.35509/01239015.747
Briceño-Morales, X., Sánchez-Castillo, O., Velásquez, J. C., Bonilla, C., Cervera, S., Guzmán-Abisaab, L., Bruges, R. E., Ángel-Aristizábal, J., Duarte, C., Lehmann-Mosquera, C., et al. (2021) · Revista Colombiana de Cancerología · doi:10.35509/01239015.746 · Cited by 1
Cáceres-Galvis, C., Rivera, M. F. U., Marín, C. R., & Ramírez, D. M. G. (2021) · Revista Colombiana de Cancerología · doi:10.35509/01239015.716
Options for Endocrine-Refractory, Hormone Receptor–Positive Breast Cancer: Which Target and When?
Borges, V. F. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01910 · Cited by 2
Hetterich, M., & Ortmann, O. (2021) · Frauenheilkunde up2date · doi:10.1055/a-1372-9388
Place of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer
Board Editorial (2021) · Journal of Modern Oncology · doi:10.26442/18151434.2021.3.201122
“PALOMA-2 (n=666) [11, 12] MONARCH-3 (n=493) [13] MONALEESA-2 (n=668) [14] MONALEESA-7 (n=672) [15, 16]”
Möbus, V. J. (2021) · Elsevier eBooks · doi:10.1016/b978-3-437-23824-6.00046-8
Therapiealgorithmen für das Mammakarzinom
Blohmer, J., Schneeweiß, A., Bauerfeind, I., Fehm, T. N., Müller, V., Thomssen, C., Witzel, I., Wöckel, A., & Janni, W. (2021) · Der Onkologe · doi:10.1007/s00761-021-01060-0
“Quellen: GnRHa plus Fulvestrant plus Palbociclib: [77, 78], GnRHa plus AI plus Palbociclib: [79], GnRHa plus AI/Tamoxifen plus Ribociclib: [80, 81], GnRHa plus Fulvestrant+ Abemaciclib: [82],GnRHaplusTamoxifen (vs.OFSoderTamoxifen): [83,84],GnRHaplusAI (Erst-oderZweitlinie): [85–87], GnRHaplus Fulvestrant: [88], OFS,…”
BackgroundInfluentialBoard Editorial (2021) · Journal of Modern Oncology · doi:10.26442/18151434.2021.4.201255
Meyer, M., Chrysou, K., Stamatiou, A., Gilabert, M., Gómez, R. G. H., Latifyan, S., Masmoudi, S., Mederos, N., Perrinjaquet, C., Berthold, D., et al. (2022) · JMIG · doi:10.53738/revmed.2022.18.767.182
Vernadou, A., Ferahta, N., Mederos, N., Ferraro, D. A., Dischl-Antonioni, I., Diciolla, A., Liapi, A., Mosimann, V., Latifyan, S., Aedo-Lopez, V., et al. (2020) · JMIG · doi:10.53738/revmed.2020.16.676-77.0072
Update Mammakarzinom 2021 Teil 2 – fortgeschrittene Stadien, Langzeitfolgen und Biomarker
Ditsch, N. C., Stickeler, E., Behrens, A. S., Belleville, E., Fasching, P. A., Fehm, T. N., Hartkopf, A. D., Jackisch, C., Janni, W., Kolberg‐Liedtke, C., et al. (2022) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/a-1755-5626
2021 Update on Systemic Therapy for Breast Cancer
Oseledchyk, A., Kurzeder, C., Kohler, A., & Vetter, M. H. F. (2022) · healthbook TIMES Oncology Hematology · doi:10.36000/hbt.oh.2022.11.070
Buhl, I. K., Christensen, T. D., Buhl, A. S. K., Christensen, I. J., Balslev, E., Knoop, A. S., Ejlertsen, B., Kümler, I., Danø, H., Luczak, A. A., et al. (2019) · Research Square · doi:10.21203/rs.2.10981/v1
“Recent successes of combining an AI or fulvestrant with a cyclin-dependent kinase (CDK) 4/6 inhibitor in ER+, human epidermal growth factor receptor 2 negative (HER2-) ABC has moved this combination to first and second line treatment (6,7).”
BackgroundEditorial Board (2021) · Journal of Modern Oncology · doi:10.26442/18151434.2021.1.200764
(2020) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1131-7106
(2019) · British journal of surgery · doi:10.1002/bjs.11357
Владимирович, С. А., & Кононенко, И. Б. (2022) · Journal of Modern Oncology · doi:10.26442/18151434.2022.2.201702 · Cited by 1
“Медиана ОВ не была достигнута в группе рибоциклиба и составила 49,6 мес в группе плацебо (ОР 0,53, 95% ДИ 0,36–0,79) [33, 34].”
InfluentialGanguly, S., & Gogia, A. (2022) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_135_22
The Use of Cyclin-Dependent Tyrosine Kinase 4/6 (CDK4/6) Inhibitors in Breast Cancer
Ali, M. M., & Mahmood, N. M. A. (2022) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v3i.79
“3 percent in the placebo arm) the average survival in the Ribociclib group was slightly longer than the placebo group, with 29 percent reduction in the risk of death in a patient with HR+/HER2- ABC [23,24] (Table 1).”
BackgroundInfluentialNeeded in Empirical Social Science: NumbersPreprint
Edlin, A. S., & Love, M. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4195779 · Cited by 2
Tripathy, D., Makhnoon, S., Arun, B. K., Şahin, A. A., Kettner, N. M., Damodaran, S., Keyomarsi, K., Yang, W. T., Hunt, K. K., Clemens, M. W., et al. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm109.pub2
Self-citation1144 IL17-producing γδ T cells promote resistance to CDK4/6 inhibitors in HR+HER2- breast cancer
Petroni, G., Gouin, K. H., Galassi, C., Buqué, A., Bloy, N., Yamazaki, T., Sato, A., Jiménez‐Cortegana, C., Kirchmair, A., Massa, C., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-sitc2022.1144
“cancer, reflecting their ability to extend progression-free survival (PFS) and overall survival (OS) in this patient population.(1-3) Nonetheless, >50% of women with HR breast”
BackgroundВладимировна, Л. Е., Tsareva, А. S., Kuznetsova, A. A., & Артамонова, Е. В. (2022) · Medical alphabet · doi:10.33667/2078-5631-2022-26-13-19
Grechukhina, K., Vorontsova, K. A., Filonenko, D., Станиславович, Т. П., Shchadrova, V. V., & Zhukova, L. (2022) · Journal of Modern Oncology · doi:10.26442/18151434.2022.3.201895
Effect of ribociclib on productivity losses due to breast cancer in young women in Brazil
Buehler, A. M., Dionne, P.-A., Chandiwana, D., Pathak, P., & Igho-Osagie, E. (2022) · Revista de Saúde Pública · doi:10.11606/s1518-8787.2022056004160
Update Mammakarzinom 2022 Teil 2 – Brustkrebs in fortgeschrittenen Krankheitsstadien
Müller, V., Welslau, M., Lüftner, D., Schütz, F., Stickeler, E., Fasching, P. A., Janni, W., Thomssen, C., Witzel, I., Fehm, T. N., et al. (2022) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/a-1951-0545
Self-citationRole of ribociclib in treatment of luminal Her-2-negative mBC with CNS metastases
Grechukhina, K., Vorontsova, K. A., Filonenko, D., Станиславович, Т. П., Shchadrova, V. V., Glebovskaya, V. V., & Zhukova, L. (2022) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2022-16-22-42-51
Espié, M., Bonnet-Bensimon, C., de Castelbajac, V., Cuvier, C., Giacchetti, S., & Teixeira, L. (2022) · EMC - Ginecología-Obstetricia · doi:10.1016/s1283-081x(22)46717-8 · Cited by 1
Davey, M. G., & Kerin, M. J. (2023) · Breast Cancer Basic and Clinical Research · doi:10.1177/11782234221145409
Ziobro, M., & Grela-Wojewoda, A. (2023) · Biomedicines · doi:10.3390/biomedicines11020510 · Cited by 3
Hepatotoxicity secondary to ribociclib and echinacea: Case report
Gonzalez, C. G. (2022) · Journal of Clinical Images and Medical Case Reports · doi:10.52768/2766-7820/2175
Engler, T., Fasching, P. A., Lüftner, D., Hartkopf, A. D., Müller, V., Kolberg, H., Hadji, P., Tesch, H., Häberle, L., Ettl, J., et al. (2023) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/a-2008-6553
“Die Analyse der progressionsfreien Überlebenszeit und der Gesamtüberlebenszeit in Abhängigkeit von den verschiedenen klinischen Therapien (▶ Abb.”
BackgroundInfluentialUpdate Mammakarzinom 2022 Teil 4 – Brustkrebs in fortgeschrittenen Krankheitsstadien
Aktas, B., Fehm, T. N., Welslau, M., Müller, V., Lüftner, D., Schütz, F., Fasching, P. A., Janni, W., Thomssen, C., Witzel, I., et al. (2023) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/a-2001-4729
Self-citationHetterich, M., & Ortmann, O. (2023) · TumorDiagnostik & Therapie · doi:10.1055/a-1942-4964
Bardia, A., Modi, S., Oliveira, M., Cortés, J., Campone, M., Ma, B. B. Y., Dirix, L. Y., Weise, A. M., Hewes, B., Díaz-Padilla, I., et al. (2023) · doi:10.1158/1078-0432.c.6529767
Self-citationLu, Y., Lee, K. S., Chao, T., Tseng, L., Chitapanarux, I., Chen, S., Liu, C.-T., Sohn, J., Kim, J. H., Chang, Y., et al. (2023) · doi:10.1158/1078-0432.c.6530189
Self-citationTolaney, S. M., Im, Y., Calvo, E., Lu, Y., Hamilton, E. P., Forero, A., Bachelot, T., Maur, M., Fasolo, A., Tiedt, R., et al. (2023) · doi:10.1158/1078-0432.c.6530064
Self-citationBardia, A., Hurvitz, S. A., DeMichele, A. M., Clark, A. S., Zelnak, A. B., Yardley, D. A., Karuturi, M. S., Sanft, T. B., Blau, S. H., Hart, L. L., et al. (2023) · doi:10.1158/1078-0432.c.6530513
Self-citationGarcía-Sáenz, J. Á., Martínez-Jáñez, N., Cubedo, R., Jerez, Y., Lahuerta, A., González-Santiago, S., Ferrer, N., Ramos, M., Alonso-Romero, J. L., Antón, A., et al. (2023) · doi:10.1158/1078-0432.c.6531135
de Kouchkovsky, I., Rao, A., Carneiro, B. A., Zhang, L., Lewis, C. J., Phone, A., Small, E. J., Friedlander, T. W., Fong, L. H., Paris, P. L., et al. (2023) · doi:10.1158/1078-0432.c.6532557
Davis, A. A., Luo, J. R., Zheng, T., Dai, C., Dong, X., Tan, L., Suresh, R., Ademuyiwa, F. O., Rigden, C. E., Rearden, T. P., et al. (2023) · doi:10.1158/1078-0432.c.6533108
de Kouchkovsky, I., Rao, A., Carneiro, B. A., Zhang, L., Lewis, C. J., Phone, A., Small, E. J., Friedlander, T. W., Fong, L. H., Paris, P. L., et al. (2023) · doi:10.1158/1078-0432.c.6532557.v1
Tolaney, S. M., Im, Y., Calvo, E., Lu, Y., Hamilton, E. P., Forero, A., Bachelot, T., Maur, M., Fasolo, A., Tiedt, R., et al. (2023) · doi:10.1158/1078-0432.c.6530064.v1
Self-citationNovick, D., Rajan, N., Wei, A. C.-C., Cheng, R., Colman, S., & Szende, Á. (2023) · Value in Health Regional Issues · doi:10.1016/j.vhri.2023.02.010
Hajir, M., Abu-Hijlih, R. A., Sheikha, A. A., Alqasem, K. S., & Abdel‐Razeq, H. (2023) · Current Problems in Cancer Case Reports · doi:10.1016/j.cpccr.2023.100243
Davis, A. A., Luo, J. R., Zheng, T., Dai, C., Dong, X., Tan, L., Suresh, R., Ademuyiwa, F. O., Rigden, C. E., Rearden, T. P., et al. (2023) · doi:10.1158/1078-0432.c.6533108.v2
Grechukhina, K., Kalugin, M. V., Prosvirnov, A. A. P., Sukhova, M. V., & Zhukova, L. (2023) · Journal of Modern Oncology · doi:10.26442/18151434.2023.1.202180
“До оглашения финальных результатов ML-2 (оценивало эффективность добавления рибоциклиба к летрозолу) было известно, что добавление рибоциклиба к фулвестранту (ML-3) и к ИА у пременопаузальных пациенток (ML-7) привело к увеличению мОВ [7, 8].”
InfluentialMüller, M., Brucker, C. V. M., & Zeder-Göß, C. (2023) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0043-1768848
Update Mammakarzinom 2022 Teil 6 – Brustkrebs in fortgeschrittenen Krankheitsstadien
Lüftner, D., Lux, M. P., Fehm, T. N., Welslau, M., Müller, V., Schütz, F., Fasching, P. A., Janni, W., Thomssen, C., Witzel, I., et al. (2023) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/a-2079-8481
Self-citationÖnner, H., Eren, O. Ö., Körez, M. K., Yılmaz, F., & Gedi̇k, G. K. (2023) · Revista Española de Medicina Nuclear e Imagen Molecular · doi:10.1016/j.remn.2023.03.002
Luminal breast cancer treatment beyond cell cycle inhibitors
Sánchez-Bayona, R., & Bianchi, M. A. (2023) · Revisiones en cáncer · doi:10.20960/revcancer.00027
Futuro y líneas de investigación clínica del cáncer de mama luminal metastásico
González-Cruz, V. I., & González, C. G. (2023) · Revisiones en cáncer · doi:10.20960/revcancer.00018
First-line treatment of hormone-sensitive metastatic breast cancer
López-Muñíz, I. C., Cárdenas, J. D., & Blas, I. O. (2023) · Revisiones en cáncer · doi:10.20960/revcancer.00031
Bielo, L. B., Natangelo, S., Katrini, J., Trapani, D., & Curigliano, G. (2023) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2023.2244870
“Ribociclib Ribociclib is currently approved for the treatment of HRpositive/HER2-negative mBC in combination with letrozole according to the MONALEESA-2 [46] and MONALEESA-7 [48], and with fulvestrant as established in the MONALEESA-3 trial [47], showing that the addition of ribociclib to endocrine therapy lead to ove…”
MethodBarańska-Bała, E., Małachowska, P., Koper, A., Wileński, S., & Koper, K. (2023) · Medical Research Journal · doi:10.5603/mrj.97119
Giannecchini, G. V., Bretas, G. O., Neves, E. K. P. B., Amorim, A. G. F., Fernandes, M. M., Lima, L. H. S. D., & Gonçalves, A. C. (2023) · Clinics of Oncology · doi:10.47829/coo.2023.7602
Hormone Treatment for Breast Cancer
Lee, S. (2023) · Korean Journal of Medicine · doi:10.3904/kjm.2023.98.6.283
Perrone, V., Dovizio, M., Leogrande, M., Tamma, A. V., Giovannitti, M., Buzzoni, C., & Esposti, L. D. (2023) · Breast Cancer Management · doi:10.2217/bmt-2023-0020 · Cited by 1
Caetano, A. C., Tavares, A., Pires, M. R., da Costa, C. B., Monteiro, J. C., Roque, R., Santos, R. A., Santos, L., Gomes, I. F., Fraga, T., et al. (2024) · F1000Research · doi:10.12688/f1000research.142460.1
How does time speak about cancer, its diagnosis, treatments, and challenges?
Ghosh, A. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95116-6.00009-8
Prat, A., Solovieff, N., André, F., O’Shaughnessy, J., Cameron, D., Janni, W., Sonke, G. S., Yap, Y. S., Yardley, D. A., Partridge, A. H., et al. (2024) · doi:10.1158/1078-0432.c.7077775
The PRC2.1 subcomplex opposes G1 progression through regulation of CCND1 and CCND2
Longhurst, A. D., Wang, K., Suresh, H. G., Ketavarapu, M., Ward, H. N., Jones, I. R., Narayan, V., Hundley, F. V., Hassan, A. Z., Boone, C. M., et al. (2025) · eLife · doi:10.7554/elife.97577.3 · Cited by 6
Systemic Therapy for Breast Cancer
Hallmeyer, S., Qamar, R., & Shamah, C. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-93249-3.00009-6
Neue Strategien beim metastasierten, endokrin sensitiven Mammakarzinom
Lüftner, D., & Wagner, K. (2024) · Die Onkologie · doi:10.1007/s00761-024-01510-5
Chiu, J. W. Y., Su, F., Joshi, M., Masuda, N., Ishikawa, T., Aruga, T., Zarate, J. P., Babbar, N., Balbin, O. A., & Yap, Y. S. (2023) · Figshare · doi:10.6084/m9.figshare.23949787
Mo, H., Liu, X., Yu, X. F., Chen, H., Guo, S., Li, Z., Wang, S., Li, C., Han, J., Fu, M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20745219
Mo, H., Liu, X., Yu, X. F., Chen, H., Guo, S., Li, Z., Wang, S., Li, C., Han, J., Fu, M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20745216
Mo, H., Liu, X., Xue, Y., Chen, H., Guo, S., Li, Z., Wang, S., Li, C., Han, J., Fu, M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20745210
Mo, H., Liu, X., Yu, X. F., Chen, H., Guo, S., Li, Z., Wang, S., Li, C., Han, J., Fu, M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20745213
Mo, H., Liu, X., Yu, X. F., Chen, H., Guo, S., Li, Z., Wang, S., Li, C., Han, J., Fu, M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20745204
Schmidt, M. (2024) · Trillium Krebsmedizin · doi:10.47184/tk.2024.02.1
Zhukova, L., Болотина, Л. В., Дворниченко, В. В., Fadeeva, N., Петровна, Г. И., Grechukhina, K., Hasanova, A. I., Kislov, N. V., Kudryavtsev, I. Y., Manikhas, A., et al. (2024) · Journal of Modern Oncology · doi:10.26442/18151434.2024.1.202595
Das metastasierte Mammakarzinom – ein Überblick zur Entwicklung der Therapiestandards 2024
Thomssen, C., & Park‐Simon, T. (2024) · Die Gynäkologie · doi:10.1007/s00129-024-05216-y
Metadata
- Authors
- Im, S.-A., Lu, Y.-S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., Chow, L., Sohn, J., Lee, K.-S., Campos-Gomez, S., Villanueva-Vazquez, R., Jung, K.-H., Chakravartty, A., Hughes, G., Gounaris, I., Rodriguez-Lorenc, K., Taran, T., Hurvitz, S., & Tripathy, D.
- Affiliations
- Seoul National University (KR)
- Harvard University (US)
- From Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), the Yonsei Cancer Center, Yonsei University Health System (J.S.), and the Asan Medical Center, University of Ulsan College of Medicine (K.-H.J.), Seoul, and the Center for Breast Cancer, National Cancer Center, Gyeonggi-do (K.-S.L.) — all in South Korea; National Taiwan University Hospital, Taipei, Taiwan (Y.-S.L.); Massachusetts General Hospital Cancer Center and Harvard...
- Novartis (Switzerland) (CH)
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-07-25
- Volume
- 381
- Issue
- 4
- Pages
- 307-316
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2948069739
- Cited by
- 1,001
- References
- 32
- Citations by year
- 2026: 68 · 2025: 119 · 2024: 121 · 2023: 152 · 2022: 159 · 2021: 165 · 2020: 174 · 2019: 42
- FWCI
- 100.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Novartis
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- ribociclib, CDK4/6 inhibitors, endocrine therapy, hormone receptor-positive breast cancer, HER2-negative breast cancer, overall survival, aromatase inhibitors, goserelin, tamoxifen, progression-free survival, disease progression, second-line therapy, antineoplastic therapy, treatment-related adverse events, neutropenia
- MeSH terms
- Adult, Aminopyridines, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Female, Follow-Up Studies, Humans, Middle Aged, Purines, Receptors, Estrogen, Receptors, Progesterone, Tamoxifen, Survival Analysis, Premenopause, Erb-b2 Receptor Tyrosine Kinases, Cyclin-Dependent Kinases, Aromatase Inhibitors, Protein Kinase Inhibitors, Perimenopause, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.